Previous Article | Next Article 
Journal of Clinical Microbiology, June 1999, p. 2104-2105, Vol. 37, No. 6
Clinical Laboratory
Department,1 Department of
Microbiology,2 and Department of
Nephrology,3 Toho University School of
Medicine, Tokyo 143, Japan
Received 29 October 1998/Returned for modification 7 February
1999/Accepted 5 March 1999
We report the first Japanese case of primary septicemia with
Shewanella alga and also describe the bacteriological
characteristics of and results of antibiotic susceptibility tests of
the isolate. S. alga was repeatedly isolated, at times
simultaneously with Escherichia coli, from the blood of a
64-year-old female undergoing hemodialysis. The isolated organism was
determined to be S. alga based on recently published
identification criteria, such as hemolysis on sheep blood agar, no acid
production from carbohydrates, and growth on agar containing 6.5%
NaCl. Results of antibiotic susceptibility tests demonstrated that the
isolate was sensitive to levofloxacin and cefpirome (MICs, We report here a case of primary Shewanella alga
septicemia and describe the bacteriological characteristics of and
antibiotic susceptibility results for the organism. A 64-year-old
female patient on hemodialysis for 5 years was admitted to the hospital because of a 5-day history of general fatigue and high-grade
fever. Her symptoms progressively
deteriorated despite the use of oral cefpodoxime proxetil. The patient
denied having been exposed to any fresh or salt water, insect bites, or
trauma or having traveled recently. Body temperature on admission was
39.4°C, and severe malaise was observed. Physical examination
demonstrated no specific signs of infections or skin manifestations.
Laboratory tests on admission showed a level of C-reactive protein of
4.2 mg/dl (normal range, 0 to 0.2 mg/dl), a leukocyte count of
6,300/mm3 (normal range, 4,000 to 9,000/mm3), a
platelet count of 80,000/mm3 (normal range, 150,000 to
400,000/mm3), and no signs of liver damage. Blood cultures
were collected, and then cefazolin (2 g/day), gentamicin (40 mg/day),
and levofloxacin (100 mg/day) were empirically started. On the second
and third days after admission, S. alga and
Escherichia coli were separately or concurrently isolated
from multiple blood culture bottles. No other pathogenic organisms were
isolated from several other specimens, including urine, stool, and
sputum. The level of C-reactive protein in serum increased to 20.9 mg/dl on the third day, but clinical symptoms and laboratory results
returned to normal thereafter. On day 7, antibiotics were changed to
minocycline (100 mg/day), cefpirome (1 g/day), and levofloxacin (100 mg/day) based on the results of broth microdilution antibiotic
sensitivity testing (Table 1). The
patient was discharged from the hospital 25 days after
admission.
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Primary Shewanella alga Septicemia in a Patient
on Hemodialysis
ABSTRACT
Top
Abstract
References
0.063) but
resistant to cefazolin, ceftizoxime, and imipenem (MICs, >128, 64, and
8 µg/ml, respectively). Although the role of S. alga as a
human pathogen has not been fully determined, accumulating data suggest
that this organism may be a potential pathogen, especially in
compromised hosts.
CASE REPORT
TABLE 1.
Results of antibiotic susceptibility testing against
isolates in this study
The blood culture isolate was a nonfermentative gram-negative rod that
was motile and oxidase positive. The organism was identified with 99%
certainty as Shewanella putrefaciens with the VITEK System (bioMerieux Vitek, Inc., Hazelwood, Mo.). Recent changes in taxonomy have suggested that several strains of previously reported S. putrefaciens probably were S. alga since general
identification systems, such as the VITEK and the API 20NE systems,
cannot distinguish between S. alga and S. putrefaciens (3). Therefore, additional biochemical and
bacteriological tests were performed to correctly identify the
organism. Species identification as S. alga in this report
was based on the criteria of Nozue et al. (11), and the results are shown in Table 2.
|
Several investigators have reported the results of antibacterial susceptibility tests of S. putrefaciens (including S. alga), in which gentamicin, piperacillin, and cefotaxime were recommended as effective agents (1, 8). Recently, Vogel et al. (13) have reported differences between S. alga and S. putrefaciens with respect to their susceptibilities to certain antimicrobial agents, including penicillin, ampicillin, and tetracycline (13). Although the present report includes only one strain of S. alga, our data suggest the therapeutic potential of levofloxacin, cefpirome, and minocycline, since an excellent clinical response was observed in our patient after administration of these agents.
Shewanella spp. are widely distributed in nature, and their natural habitats are water and soil (10). Shewanella putrefaciens is an uncommon cause of human disease, and isolates from clinical specimens usually indicate colonization. On the other hand, several reports have demonstrated the association of this organism with otitis media, infected ulcers of the lower limbs, and systemic infections in patients with severe debility, liver disease, or malignancy (1, 2, 4, 6, 8).
Although S. putrefaciens is the predominant human pathogen within the genus, several investigators have reported the genetic heterogeneity of this organism. Gilardi (5) recognized three distinct biovars within S. putrefaciens, while Weyant et al. recognized two biotypes based upon biochemical and phenotypic characteristics (14). In 1990, Simidu et al. (12) proposed the name S. alga for a tetrodotoxin-producing isolate recovered from red algae. Later, this strain was shown to be genetically related to S. putrefaciens, and it was subsequently determined that some strains previously reported to be S. putrefaciens were S. alga (11). In 1996, the first two Danish patients with S. alga bacteremia and lower leg ulcers were reported (3).
Since S. putrefaciens was first isolated from humans by King in 1964 (9), the number of case reports describing this organism as a human pathogen has increased in recent years. However, most human isolates of S. putrefaciens occur as part of a mixed bacterial flora, which may overshadow the clinical significance of infections caused by this organism. With our patient, E. coli was isolated concurrently with S. alga, and both organisms were considered pathogenic because of the serial isolation of these organisms from the blood. Recently, Khashe and Janda (7) demonstrated that S. alga was more virulent than S. putrefaciens in an experimental study using mice and suggested that S. alga may be the predominant human pathogen among Shewanella species.
Further studies, including determination of bacterial virulence factors, risk factors of the host, and response to antibacterial therapy, are necessary to define the pathogenic role of this organism in humans.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology, Toho University School of Medicine, 5-21-16 Ohmori-nishi, Ohtaku, Tokyo 143, Japan. Phone: 81-3-3762-4151, ext. 2397. Fax: 81-3-5493-5415. E-mail: kazu{at}med.toho-u.ac.jp.
| |
REFERENCES |
|---|
|
Top
Abstract
References
|
|---|
| 1. | Brink, A. J., A. van Straten, and A. J. van Rensburg. 1995. Shewanella (Pseudomonas) putrefaciens bacteremia. Clin. Infect. Dis. 20:1327-1332[Medline]. |
| 2. | Chen, Y. S., Y. C. Liu, M. Y. Yen, J. H. Wang, J. H. Wang, S. R. Wann, and D. L. Cheng. 1997. Skin and soft-tissue manifestations of Shewanella putrefaciens infection. Clin. Infect. Dis. 25:225-229[Medline]. |
| 3. | Dominguez, H., B. F. Vogel, L. Gram, S. Hoffmann, and S. Schaebel. 1996. Shewanella alga bacteremia in two patients with lower leg ulcers. Clin. Infect. Dis. 22:1036-1039[Medline]. |
| 4. | Gilardi, G. L. 1972. Infrequently encountered Pseudomonas species causing infection in humans. Ann. Intern. Med. 77:211-215. |
| 5. | Gilardi, G. L. 1985. Cultural and biochemical aspects for identification of glucose-nonfermenting gram-negative rods, p. 17-84. In G. L. Gilardi (ed.), Nonfermentative gram-negative rods. Marcel Dekker, Inc., New York, N.Y. |
| 6. |
Holmes, B.,
S. P. Lapage, and H. Malnick.
1975.
Strains of Pseudomonas putrefaciens from clinical material.
J. Clin. Pathol.
28:149-155 |
| 7. |
Khashe, S., and J. M. Janda.
1998.
Biochemical and pathogenic properties of Shewanella alga and Shewanella putrefaciens.
J. Clin. Microbiol.
36:783-787 |
| 8. | Kim, J. H., R. A. Cooper, K. E. Welty-Wolf, L. J. Harrell, P. Zwadyk, and M. E. Klotman. 1989. Pseudomonas putrefaciens bacteremia. Rev. Infect. Dis. 11:97-104[Medline]. |
| 9. | King, E. O. 1964. The identification of unusual pathogenic gram-negative bacteria. National Communicable Disease Center, Atlanta, Ga. |
| 10. |
Kueh, C. S.,
P. Kutarski, and M. Brunton.
1992.
Contaminated marine wounds the risk of acquiring acute bacterial infection from marine recreational beaches.
J. Appl. Bacteriol.
73:412-420[Medline].
|
| 11. |
Nozue, H.,
T. Hayashi,
Y. Hashimoto,
T. Ezaki,
K. Hamasaki,
K. Ohwada, and Y. Terawaki.
1992.
Isolation and characterization of Shewanella alga from human clinical specimens and emendation of the description of S. alga Simidu et al., 1990, 335.
Int. J. Syst. Bacteriol.
42:628-634 |
| 12. |
Simidu, U.,
K. Kita-Tsukamoto,
T. Yasumoto, and M. Yotsu.
1990.
Taxonomy of four marine bacterial strains that produce tetrodotoxin.
Int. J. Syst. Bacteriol.
40:331-336 |
| 13. | Vogel, B. F., K. Jorgensen, H. Christensen, J. E. Olsen, and L. Gram. 1997. Differentiation of Shewanella putrefaciens and Shewanella alga on the basis of whole-cell protein profiles, ribotyping, phenotypic characterization, and 16S rRNA gene sequence analysis. App. Environ. Microbiol. 63:2189-2199[Abstract]. |
| 14. | Weyant, R. C., C. W. Moss, R. E. Weaver, D. G. Hollis, J. G. Jordan, E. C. Cook, and M. I. Daneshvr. 1995. Identification of unusual pathogenic gram-negative aerobic and facultatively anaerobic bacteria, 2nd ed. Williams & Wilkins, Baltimore, Md. |
Journal of Clinical Microbiology, June 1999, p. 2104-2105, Vol. 37, No. 6
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Richards, G. P., Watson, M. A., Crane, E. J. III, Burt, I. G., Bushek, D.
(2008). Shewanella and Photobacterium spp. in Oysters and Seawater from the Delaware Bay. Appl. Environ. Microbiol.
74: 3323-3327
[Abstract] [Full Text] -
Kim, D.-M., Kang, C.-I., Lee, C. S., Kim, H.-B., Kim, E.-C., Kim, N. J., Oh, M.-d., Choe, K.-W.
(2006). Treatment Failure Due to Emergence of Resistance to Carbapenem during Therapy for Shewanella algae Bacteremia.. J. Clin. Microbiol.
44: 1172-1174
[Abstract] [Full Text] -
Botelho-Nevers, E., Gouriet, F., Rovery, C., Paris, P., Roux, V., Raoult, D., Brouqui, P.
(2005). First Case of Osteomyelitis Due to Shewanella algae. J. Clin. Microbiol.
43: 5388-5390
[Abstract] [Full Text] -
Pagani, L., Lang, A., Vedovelli, C., Moling, O., Rimenti, G., Pristera, R., Mian, P.
(2003). Soft Tissue Infection and Bacteremia Caused by Shewanella putrefaciens. J. Clin. Microbiol.
41: 2240-2241
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»